Literature DB >> 15671811

An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine.

Roberto Manfredi, Leonardo Calza, Francesco Chiodo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15671811     DOI： 10.1097/01.qai.0000143037.70120.fc

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  4 in total

1.  Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells.

Authors:  N Apostolova; L J Gomez-Sucerquia; A Moran; A Alvarez; A Blas-Garcia; J V Esplugues
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults.

Authors:  Leigh Anne Redhage; Ayumi Shintani; David W Haas; Nkiruka Emeagwali; Milica Markovic; Ikwo Oboho; Christopher Mwenya; Husamettin Erdem; Edward P Acosta; Jason D Morrow; Todd Hulgan
Journal:  HIV Clin Trials       Date:  2009 May-Jun

3.  Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.

Authors:  Giovanni Guaraldi; Stefano Zona; Gabriella Orlando; Federica Carli; Chiara Stentarelli; Kety Luzi; Elisa Garlassi; Marianna Menozzi; Pietro Bagni; Fulvio Adorni
Journal:  Clin Drug Investig       Date:  2011-11-01       Impact factor: 2.859

4.  In vitro and in vivo effects of IGF-I on adiposity in HIV-associated metabolic disease: a pilot study.

Authors:  Roy J Kim; Sumit Vaghani; Larisa M Zifchak; Joseph H Quinn; Weimian He; Pablo Tebas; Ian Frank
Journal:  Arch Med Res       Date:  2013-07-16       Impact factor: 2.235
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.